Kopran Limited Publishes Merger Notice; Stakeholder Meetings on June 3

3 min read     Updated on 04 May 2026, 05:08 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Kopran Limited has published newspaper advertisements regarding the merger with Kopran Laboratories Limited following NCLT order dated April 9, 2026. Six stakeholder meetings are scheduled for June 3, 2026, through video conferencing with remote e-voting available from May 27 to June 2. The merger scheme under Companies Act, 2013 requires approval from all stakeholder categories and subsequent NCLT sanction.

powered bylight_fuzz_icon
39099485

*this image is generated using AI for illustrative purposes only.

Kopran Limited has published newspaper advertisements on May 2, 2026, in Free Press Journal (English) and Navshakti (Marathi) pursuant to the directions of the National Company Law Tribunal, Mumbai Bench, vide Order dated April 9, 2026. The publication serves as notice to members, secured creditors, and unsecured creditors for the approval of the Scheme of Amalgamation (Merger by Absorption) of Kopran Laboratories Limited (the Transferor Company) with Kopran Limited (the Transferee Company).

Meeting Schedule and E-Voting Details

The NCLT has convened six separate meetings for different stakeholder categories of both entities, all to be conducted through video conferencing and other audio-visual means on Wednesday, June 3, 2026. Remote e-voting facilities will be available from Wednesday, May 27, 2026, at 9:00 a.m. IST until Tuesday, June 2, 2026, at 5:00 p.m. IST.

Company Stakeholder Category Date Time (IST)
Kopran Limited Equity Shareholders June 3, 2026 10.00 a.m.
Kopran Limited Secured Creditors June 3, 2026 11.30 a.m.
Kopran Limited Unsecured Creditors June 3, 2026 1.00 p.m.
Kopran Laboratories Limited Equity Shareholders June 3, 2026 2.30 p.m.
Kopran Laboratories Limited Secured Creditors June 3, 2026 3.30 p.m.
Kopran Laboratories Limited Unsecured Creditors June 3, 2026 5.00 p.m.

Merger Framework and Key Dates

The proposed transaction involves a scheme of amalgamation through merger by absorption under Sections 230 to 232 of the Companies Act, 2013. Notices were dispatched to stakeholders on April 30, 2026, through email at registered addresses and via courier on May 2, 2026, where email service was not possible. The cut-off date for notice dispatch was April 24, 2026, while the cut-off date for e-voting is May 22, 2026.

Meeting Officials and Documentation

Ms. Nina Lath Gupta (Ex. IRS and Ex-MD, NFDI) has been appointed as Chairperson for the meetings, with Mr. Narayan Tulsiram Tati as alternate. Ms. Smita Vinayak Prabhu of M/s. Smita Prabhu & Associates has been appointed as Scrutinizer. Complete meeting notices, explanatory statements, and annexures are available on the company's websites at www.kopran.com and www.kopranlaboratories.com , as well as on BSE, NSE, and NSDL portals. The results will be announced within two working days from the conclusion of the meetings.

Regulatory Compliance

The announcement has been made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The communication, signed by Company Secretary and Compliance Officer Sunil Sodhani, has been formally submitted to both BSE Limited and The National Stock Exchange of India Limited. The scheme, if approved at the NCLT-convened meetings, will be subject to subsequent approval of the Hon'ble NCLT, Mumbai Bench.

Source: None/Company/INE082A01010/1c833258-6a84-416c-a8f3-ade75f286715.pdf

Historical Stock Returns for Kopran

1 Day5 Days1 Month6 Months1 Year5 Years
-2.43%+3.32%+6.84%+26.88%-15.07%-14.68%

What share swap ratio has been proposed for Kopran Laboratories Limited shareholders, and how does it compare to the current market valuations of both entities?

How might the absorption of Kopran Laboratories Limited into Kopran Limited impact the combined entity's revenue, debt profile, and competitive positioning in the Indian pharmaceutical market?

If secured or unsecured creditors vote against the scheme, what alternative restructuring options could Kopran Limited pursue to achieve its consolidation objectives?

NCLT Directs Kopran Limited to Hold Stakeholder Meetings for Proposed Merger with Kopran Laboratories

1 min read     Updated on 10 Apr 2026, 11:33 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Kopran Limited received NCLT Mumbai Bench directions on April 09, 2026, to conduct stakeholder meetings for its proposed merger with Kopran Laboratories Limited. The tribunal mandated separate meetings for equity shareholders, secured creditors, and unsecured creditors as part of the Scheme of Amalgamation under the Companies Act 2013. This development advances the merger by absorption process initially announced in March 2025, with the complete NCLT order now available on the company's website for stakeholder review.

powered bylight_fuzz_icon
37389806

*this image is generated using AI for illustrative purposes only.

Kopran Limited has received a significant regulatory milestone in its proposed merger process, with the National Company Law Tribunal (NCLT) Mumbai Bench directing the company to conduct mandatory stakeholder meetings. The development marks a crucial step forward in the pharmaceutical company's consolidation strategy.

NCLT Order Details

The Hon'ble NCLT Mumbai Bench issued its order on April 09, 2026, providing specific directions for the merger process. The tribunal has mandated Kopran Limited to organize separate meetings for different stakeholder categories as part of the amalgamation scheme.

Meeting Type: Stakeholder Category
Equity Shareholders Meeting: All equity shareholders
Secured Creditors Meeting: Secured creditors
Unsecured Creditors Meeting: Unsecured creditors

Merger Scheme Overview

The proposed transaction involves the Scheme of Amalgamation through merger by absorption of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company). The scheme was initially announced in the company's letter dated March 20, 2025, and operates under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.

Parameter: Details
Merger Type: Merger by Absorption
Transferor Company: Kopran Laboratories Limited
Transferee Company: Kopran Limited
Legal Framework: Companies Act 2013, Sections 230-232
Status: Subject to regulatory approvals

Regulatory Compliance

The disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations. Company Secretary and Compliance Officer Sunil Sodhani signed the regulatory filing, ensuring compliance with stock exchange notification requirements.

Document Accessibility

The complete NCLT order is now publicly available on the company's official website at www.kopran.com . Stakeholders can access the detailed order through the dedicated link provided in the company's regulatory filing, ensuring transparency in the merger process.

The NCLT's direction represents a procedural advancement in the merger timeline, bringing the pharmaceutical company closer to completing its consolidation objectives. The mandated stakeholder meetings will provide the necessary forum for shareholders and creditors to review and approve the proposed amalgamation scheme.

Historical Stock Returns for Kopran

1 Day5 Days1 Month6 Months1 Year5 Years
-2.43%+3.32%+6.84%+26.88%-15.07%-14.68%

What potential synergies and cost savings could Kopran Limited achieve post-merger, and how might this impact its competitive position in the pharmaceutical market?

How will the merger affect Kopran's product portfolio diversification and its ability to compete with larger pharmaceutical companies?

What are the expected timelines for completing the stakeholder meetings and receiving final NCLT approval for the amalgamation?

More News on Kopran

1 Year Returns:-15.07%